Cobitolimod

Drug Profile

Cobitolimod

Alternative Names: Antisense oligonucleotide NF-KB-p65; DIMS-0150; Kappaproct

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator InDex Pharmaceuticals
  • Class Anti-inflammatories; Antiulcers; Oligodeoxyribonucleotides
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ulcerative colitis
  • Phase I Brain oedema

Most Recent Events

  • 13 Sep 2017 InDex Pharmaceuticals has patent protection for cobitolimod in Japan
  • 09 Aug 2017 Cobitolimod receives Orphan Drug status for Ulcerative colitis (In children) in USA
  • 06 Jul 2017 InDex Pharmaceuticals has patent protection for cobitolimod in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top